Home LiteratureArticle Details
PMID: 8473515 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

The Journal of clinical investigation ·Vol. 91 ·No. 4 ·1993-04-00 ·Pages 1753-60

Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA

Abstract

The p53 gene was analyzed in tumor specimens obtained from 52 patients with various types of carcinoma of the thyroid gland by a combined molecular and immunocytochemical approach. The histologic types included 37 well-differentiated papillary and follicular carcinomas, 8 poorly differentiated, and 7 undifferentiated carcinomas. The p53 gene was shown to be unaffected in all differentiated tumors by single-strand conformation polymorphism analysis. However, in two out of eight (25%) of poorly differentiated carcinomas and five out of seven (71%) undifferentiated carcinomas, p53 mutations were identified and subsequently characterized by DNA sequencing. One undifferentiated carcinoma displayed two areas with varying degrees of differentiation. The comparative analysis of the p53 gene, in both the more and the less differentiated area of this tumor, clearly showed that the p53 mutation was confined to the latter component of the tumor specimen. These results indicate that mutations of the p53 gene are associated with the most aggressive histologic types of thyroid tumors, such as the undifferentiated carcinoma and, to a certain extent, the poorly differentiated carcinoma, and that the alterations of this gene represent a late genetic event in human thyroid carcinogenesis.

Related Genes
MeSH Terms
Adult Aged Carcinoma/genetics,pathology DNA, Single-Stranded Female Genes, p53/genetics Humans Immunohistochemistry Male Middle Aged Mutation Nucleic Acid Conformation Polymorphism, Genetic Thyroid Neoplasms/genetics,pathology
Chemicals
DNA, Single-Stranded
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Donghi R
Divisione di Oncologia Sperimentale A, Istituto Nazionale Tumori, Milan, Italy.
Longoni A
Pilotti S
Michieli P
Della Porta G
Pierotti M A
References (32)
32 references, click to expand
  1. The p53 tumour suppressor gene.
    Nature. 1991 Jun 6;351(6326):453-6 PMID: 2046748
  2. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues.
    J Pathol. 1992 Sep;168(1):85-6 PMID: 1453271
  3. p53 mutations in human cancers.
    Science. 1991 Jul 5;253(5015):49-53 PMID: 1905840
  4. Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases.
    Am J Clin Pathol. 1991 Jul;96(1):15-24 PMID: 1712540
  5. Silver enhancement of nickel-diaminobenzidine as applied to single and double immunoperoxidase staining.
    Biotech Histochem. 1991;66(3):159-67 PMID: 1716167
  6. p53 mutations in ovarian cancer: a late event?
    Oncogene. 1991 Sep;6(9):1685-90 PMID: 1923532
  7. Polymorphism at codon 213 within the p53 gene.
    Oncogene. 1991 Sep;6(9):1691-2 PMID: 1923533
  8. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
    Oncogene. 1991 Sep;6(9):1693-7 PMID: 1923534
  9. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.
    Cancer Res. 1992 Mar 1;52(5):1369-71 PMID: 1737400
  10. Clonal expansion of p53 mutant cells is associated with brain tumour progression.
    Nature. 1992 Feb 27;355(6363):846-7 PMID: 1311419
  11. A new TaqI polymorphism in the p53 gene.
    Nucleic Acids Res. 1992 Feb 25;20(4):928 PMID: 1347421
  12. The aetiology of thyroid tumours.
    Clin Endocrinol Metab. 1979 Mar;8(1):193-207 PMID: 428139
  13. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas.
    Cancer. 1983 Nov 15;52(10):1849-55 PMID: 6313176
  14. Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma".
    Am J Surg Pathol. 1984 Sep;8(9):655-68 PMID: 6476195
  15. Prognostic implications of the tall cell variant of papillary thyroid carcinoma.
    Am J Surg Pathol. 1988 Jan;12(1):22-7 PMID: 3337337
  16. Improved double-stranded DNA sequencing using the linear polymerase chain reaction.
    Nucleic Acids Res. 1989 Nov 11;17(21):8889 PMID: 2587244
  17. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma.
    Oncogene. 1989 Dec;4(12):1457-62 PMID: 2594368
  18. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.
    Cell. 1990 Feb 23;60(4):557-63 PMID: 2406025
  19. Presence of mutations in all three ras genes in human thyroid tumors.
    Oncogene. 1990 Apr;5(4):565-70 PMID: 2183158
  20. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
    EMBO J. 1990 May;9(5):1595-602 PMID: 1691710
  21. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases.
    Cancer. 1990 Jul 15;66(2):321-30 PMID: 1695118
  22. Structural aspects of the p53 protein in relation to gene evolution.
    Oncogene. 1990 Jul;5(7):945-52 PMID: 2142762
  23. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Oncogene. 1990 Oct;5(10):1603-10 PMID: 1979160
  24. Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation.
    Oncogene. 1991 Mar;6(3):471-3 PMID: 2011403
  25. The trk proto-oncogene encodes a receptor for nerve growth factor.
    Cell. 1991 Apr 5;65(1):189-97 PMID: 1849459
  26. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.
    Cancer Res. 1991 May 15;51(10):2690-3 PMID: 2021946
  27. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections.
    J Histochem Cytochem. 1991 Jun;39(6):741-8 PMID: 1709656
  28. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.
    Oncogene. 1992 Feb;7(2):237-42 PMID: 1532241
  29. Papillary thyroid carcinoma in Kanazawa, Japan: prognostic significance of histological subtypes.
    Histopathology. 1992 Mar;20(3):243-50 PMID: 1563711
  30. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.
    J Clin Invest. 1992 May;89(5):1517-22 PMID: 1569189
  31. P53 in tumour pathology: can we trust immunocytochemistry?
    J Pathol. 1992 Apr;166(4):329-30 PMID: 1517889
  32. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
    Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5413-7 PMID: 2052620
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1993-04-00
Pages
1753-60
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC288155
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com